EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cholesteatoma Recidivism in Pediatric Versus Adult Patients: Disease Extent and Prognostic Factors

Michal Homolac, Anna Svejdova, Lukas Skoloudik, Jan Mejzlik, Jana Dedkova, Viktor Chrobok

The Laryngoscope · 2026-11-05

DOI: 10.1002/lary.71038 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective To determine whether pediatric age independently predicts cholesteatoma recidivism beyond anatomical disease extent using the EAONO/JOS and SAMEO‐ATO classifications. Methods A retrospective cohort study of 128 primary cholesteatoma surgeries (128 ears in 126 patients; median follow‐up, 5.8 years) was conducted. Etiology, stage, topographical extension (STAM), and surgical category (SAMEO‐ATO) were recorded. A data‐driven threshold (< 20 years) was identified via maximally selected rank statistics. Predictors were determined by Group Lasso selection and Firth's penalized Cox regression. Results Recidivism was identified in 21 of 43 pediatric and 16 of 85 adult ears. The 5‐year cumulative risk was 53.9% (95% CI, 34.2%–67.8%) in children versus 19.1% (95% CI, 9.5%–27.7%) in adults (log‐rank p < 0.001), driven by early residual disease ( p = 0.004) rather than true recurrence ( p = 0.058). The sinus tympani (S2) was a site of recidivism in 38.5% of pediatric versus 5.6% of adult cases ( p = 0.016). Multivariable analysis identified four independent predictors: pediatric age (hazard ratio [HR] 2.24; 95% CI, 1.09–4.63), supratubal recess involvement (HR 3.41; 95% CI, 1.56–7.45), mastoid extension (HR 2.43; 95% CI, 1.01–5.84), and absence of mastoidectomy relative to canal wall‐down technique (HR 8.67; 95% CI, 1.95–38.41). Conclusion Pediatric age, supratubal recess involvement, mastoid extension, and mastoidectomy omission relative to canal wall‐down technique independently predict cholesteatoma recidivism. The predominance of residual over recurrent disease, with a median detection interval of approximately 14 months, supports active 12–18 month postoperative surveillance and long‐term clinical follow‐up on a risk‐stratified basis. Level of Evidence 3.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →